Telix Pharmaceuticals Achieves Positive Phase 3 Results for Prostate Cancer Imaging Agent in China
核心洞察
Telix Pharmaceuticals announced positive Phase 3 results for TLX591-CDx (Illuccix) in Chinese prostate cancer patients, achieving a 94.8% positive predictive value for tumor detection.
The study of 140 patients with biochemical recurrence demonstrated high accuracy across all PSA levels and metastatic locations, with 67.2% of patients experiencing treatment plan changes.
The company is progressing FDA resubmissions for TLX101-CDx (glioma imaging) and TLX250-CDx (kidney cancer imaging) following productive regulatory meetings.
Telix Pharmaceuticals Limited announced positive top-line results from its Phase 3 registration study of TLX591-CDx (Illuccix) for prostate cancer imaging in Chinese patients, setting the stage for a near-term New Drug Application submission in China. The study met its primary endpoint with a patient-level positive predictive value of 94.8% for tumor detection in patients with biochemical recurrence of prostate cancer.
Strong Clinical Performance Across Patient Populations
The Phase 3 prospective, open-label, single-arm, multicenter study conducted in collaboration with Grand Pharmaceutical Group (搜索) Limited enrolled 140 patients and delivered robust results. The overall patient-level positive predictive value of 94.8% (95% confidence interval: 85.9%, 98.2%) significantly exceeded the performance threshold agreed with the Chinese regulator, with the lower bound of the 95% CI reaching 85.9%.
The imaging agent demonstrated consistently high performance across different anatomical regions. Region-level positive predictive values reached 100.0% in the prostate bed and in extra-pelvic soft tissue, lymph nodes, and organ metastases (non-bone), 94.7% in the pelvic region outside of the prostate bed including lymph nodes, and 87.0% in bone metastases.
Notably, TLX591-CDx PSMA (搜索)-PET imaging maintained high positive predictive value across all patient groups, including those with very low baseline prostate-specific antigen levels, demonstrating broad clinical applicability.
Significant Impact on Clinical Decision-Making
The study revealed substantial clinical utility, with more than two-thirds (67.2%) of patients experiencing a change in their treatment plan as a consequence of TLX591-CDx PSMA (搜索)-PET imaging compared with the initial plan at baseline. This outcome confirms that PSMA-PET imaging with TLX591-CDx had a meaningful impact on clinical decision-making in Chinese patients, potentially leading to improved treatment strategies for participants with biochemical recurrence.
Dr. David N. Cade, Group Chief Medical Officer at Telix, commented, "This is an outstanding result. The primary endpoint of the study was met decisively, with the positive predictive value significantly exceeding the performance threshold agreed with the Chinese regulator. Importantly, the high PPV was consistent even in patients with very low PSA values, and across differing metastatic locations, demonstrating broad clinical applicability."
Strategic Market Opportunity in China
The positive results position Telix to enter a strategically important market. In China, more than 134,000 men were diagnosed with prostate cancer in 2022, with cases increasing by approximately 6% each year. The healthcare infrastructure is expanding to support nuclear medicine applications, with the number of PET/CT cameras installed in China expected to surpass 1,600 by the end of 2025, compared with 133 in 2010.
FDA Resubmission Progress for Additional Candidates
Telix provided updates on two other precision medicine candidates undergoing FDA review. The company's New Drug Application resubmission for TLX101-CDx (Pixclara, 18F-floretyrosine), a PET imaging candidate for glioma, is progressing well following collaborative interactions with the FDA around providing additional clinical data and a revised statistical analysis plan.
Following a productive Type A meeting to review the basis of the Complete Response Letter, Telix is currently finalizing its resubmission package. The company expects to provide a near-term update when the resubmission has been filed and accepted by the FDA.
For TLX250-CDx (Zircaix, 89Zr-DFO-girentuximab), a PET imaging candidate for clear cell renal cell carcinoma, Telix recently participated in a Type A meeting to discuss the Complete Response Letter received following review of the Biologics License Application. The company believes it has reached alignment with the FDA on remediation of identified deficiencies regarding the product's chemistry, manufacturing, and controls package.
The FDA has granted Telix an additional meeting in January to review the company's plan for additional data requested to establish comparability between the drug product used in the ZIRCON Phase 3 clinical trial and the scaled-up manufacturing process intended for commercial use.
Both TLX101-CDx and TLX250-CDx maintain active Expanded Access Programs, reflecting Telix's commitment to serving patients while regulatory processes continue.